Ok_老虎社区_美港股上老虎

userTesting
2021-11-09

Bangladesh's Beximco to sell generic version of Merck COVID-19 pill

Nov 9 (Reuters) - Bangladesh's Beximco Pharmaceuticals Ltd will start selling a generic version of M

Bangladesh's Beximco to sell generic version of Merck COVID-19 pill

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":844574653,"tweetId":"844574653","gmtCreate":1636448174465,"gmtModify":1636448174630,"author":{"id":4088669104286650,"authorId":4088669104286650,"authorIdStr":"4088669104286650","name":"userTesting","avatar":"https://static.tigerbbs.com/3b24fe7742aefda3019ec9856567b065","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":4,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Ok</p></body></html>","htmlText":"<html><head></head><body><p>Ok</p></body></html>","text":"Ok","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/844574653","repostId":1137172640,"repostType":4,"repost":{"id":"1137172640","pubTimestamp":1636447803,"share":"https://www.laohu8.com/m/news/1137172640?lang=&edition=full","pubTime":"2021-11-09 16:50","market":"us","language":"en","title":"Bangladesh's Beximco to sell generic version of Merck COVID-19 pill","url":"https://stock-news.laohu8.com/highlight/detail?id=1137172640","media":"Reuters","summary":"Nov 9 (Reuters) - Bangladesh's Beximco Pharmaceuticals Ltd will start selling a generic version of M","content":"<p>Nov 9 (Reuters) - Bangladesh's Beximco Pharmaceuticals Ltd will start selling a generic version of Merck &amp; Co's antiviral pill for COVID-19 following local regulatory approval, it said on Tuesday.</p>\n<p>The announcement marks the launch of the world's first generic version of Merck and Ridgeback Biotherapeutics' tablet, molnupiravir, which has been touted as a potential game-changer in the fight against the coronavirus.</p>\n<p>Molnupiravir received its first regulatory approval globally, in the UK last week. It is still under review in the United States and Europe.</p>\n<p>Beximco will soon begin selling generic molnupiravir, a cheaper version of Merck's branded pill, in Bangladesh, as it received emergency use authorisation for the treatment from the country's Directorate General of Drug Administration, it said in a statement. Exports would depend on regulatory approvals globally, it added.</p>\n<p>Merck did not immediately respond to a request for comment.</p>\n<p>The U.S. drugmaker has entered into licensing agreements with at least eight Indian drugmakers for molnupiravir, aiming to turn the South Asian nation into a manufacturing hub to supply low- and middle-income nations.</p>\n<p>These include Dr Reddy's Laboratories, Cipla , Sun Pharma, Torrent Pharmaceuticals , Emcure Pharmaceuticals and Hetero, among others.</p>\n<p>Beximco said it doesn't expect sales of the generic molnupiravir to significantly boost revenues, given the currently low COVID-19 infection rate in Bangladesh, which neighbours India.</p>\n<p>Its London-listed shares were up 6.2% at 107.25 pence by 0825 GMT.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bangladesh's Beximco to sell generic version of Merck COVID-19 pill</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBangladesh's Beximco to sell generic version of Merck COVID-19 pill\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-09 16:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/1-bangladeshs-beximco-sell-generic-083714955.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 9 (Reuters) - Bangladesh's Beximco Pharmaceuticals Ltd will start selling a generic version of Merck & Co's antiviral pill for COVID-19 following local regulatory approval, it said on Tuesday.\nThe...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-bangladeshs-beximco-sell-generic-083714955.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/1-bangladeshs-beximco-sell-generic-083714955.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137172640","content_text":"Nov 9 (Reuters) - Bangladesh's Beximco Pharmaceuticals Ltd will start selling a generic version of Merck & Co's antiviral pill for COVID-19 following local regulatory approval, it said on Tuesday.\nThe announcement marks the launch of the world's first generic version of Merck and Ridgeback Biotherapeutics' tablet, molnupiravir, which has been touted as a potential game-changer in the fight against the coronavirus.\nMolnupiravir received its first regulatory approval globally, in the UK last week. It is still under review in the United States and Europe.\nBeximco will soon begin selling generic molnupiravir, a cheaper version of Merck's branded pill, in Bangladesh, as it received emergency use authorisation for the treatment from the country's Directorate General of Drug Administration, it said in a statement. Exports would depend on regulatory approvals globally, it added.\nMerck did not immediately respond to a request for comment.\nThe U.S. drugmaker has entered into licensing agreements with at least eight Indian drugmakers for molnupiravir, aiming to turn the South Asian nation into a manufacturing hub to supply low- and middle-income nations.\nThese include Dr Reddy's Laboratories, Cipla , Sun Pharma, Torrent Pharmaceuticals , Emcure Pharmaceuticals and Hetero, among others.\nBeximco said it doesn't expect sales of the generic molnupiravir to significantly boost revenues, given the currently low COVID-19 infection rate in Bangladesh, which neighbours India.\nIts London-listed shares were up 6.2% at 107.25 pence by 0825 GMT.","news_type":1},"isVote":1,"tweetType":1,"viewCount":379,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

Bangladesh's Beximco to sell generic version of Merck COVID-19 pill

评论（1）

热议股票